And with the progression of CKD, the utilization rate of renin-angiotensin system inhibitors (RASi) and oral hypoglycemic drugs (OHD) gradually declined, while the proportion of insulin use progressively increased. The gene discussed is INS; the disease is chronic kidney disease.